A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, double-blind, placebo- and active-controlled, Phase II,
parallel-group study of up to four weeks in duration. The study consisted of a screening
visit followed by a one-week single blind placebo period. At next visit, each subject was
randomized to one of four treatment groups: 90 mcg levalbuterol, 180 mcg levalbuterol, 180
mcg racemic albuterol, or placebo. All study medication was administered as 2 actuations 4
times a day for 21 days.